Israeli-based Kamada Ltd. specializes in plasma-derived protein therapeutics and operates in two segments, Proprietary Products and Distribution. The company's offerings include a range of treatments such as WINRHO SDF for immune thrombocytopenic purpura, HEPAGAM B for prevention of hepatitis B recurrence after a liver transplant, and GLASSIA for intravenous AATD. Kamada also provides KamRho (D) IM for newborn hemolytic disease prophylaxis, snake bite antiserum, and IVIG for immunodeficiency-related conditions. Additionally, the company offers various products such as Factor VIII for hemophilia type A and IX for hemophilia type B. Kamada markets its products through strategic partnerships with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. The company was incorporated in 1990 and maintains its headquarters in Rehovot, Israel.
Kamada Ltd.'s ticker is KMDA
The company's shares trade on the NASDAQ stock exchange
They are based in Rehovot, Israel
There are 201-500 employees working at Kamada Ltd.
It is https://www.kamada.com/
Kamada Ltd. is in the Healthcare sector
Kamada Ltd. is in the Biotechnology industry
The following five companies are Kamada Ltd.'s industry peers: